Metabolism is the process through which the body generates energy from food. Food comprises biomolecules, including carbohydrates, proteins, and fats. Chemicals in the digestive system are used to break the food into sugars and acids. Metabolic disorders disrupt the normal function of metabolic processes and lead to excess or lack of essential components that are needed to stay healthy. These disorders are either inherited or acquired during the lifetime of an individual.

Factors such as increase in the cases of metabolic disorders, rise in awareness about the availability of therapeutics for metabolic disorders, increase in demand for one-time therapies for metabolic disorders, commencement of patient assistance programs for providing treatment for a range of metabolic disorders, rapid advancements in technology, rise in the prevalence of diabetes and obesity, and initiatives were undertaken by the government are expected to drive the metabolic disorder therapeutics market in the coming years. However, low compliance and adherence rates for metabolic disorder therapies and the availability of alternative options for treatment are expected to hinder the metabolic disorder therapeutics market during the forecast period.

According to the American Diabetes Association, in 2015, approximately 30.3 million Americans, or about 9.4% of the population, suffered from diabetes. In the U.S., about 1.25 million children and adults have type 1 diabetes.

According to the World Health Organization (WHO), the global prevalence of diabetes among adults over 18 years of age has increased from 4.7% in 1980 to 8.5% in 2014. The prevalence of diabetes has been rising more steadily in middle- and low-income countries.

According to the World Health Organization (WHO), in 2016, globally more than 1.9 billion adults aged 18 years and older were categorized as overweight. Out of these, over 650 million were categorized as obese.

According to the Centers for Disease Control and Prevention (CDC), having increased blood cholesterol puts people at risk of heart disease, and it is considered to be the leading cause of death in the U.S. The risk of heart disease for people with high cholesterol is about twice as high compared to that for people with low cholesterol. Approximately 71 million adults in the U.S. are estimated to have high low-density lipoproteins (LDL) or bad cholesterol. About 7% of children and adolescents between the ages of 6 and 19 have high total cholesterol. High cholesterol has no symptoms. Therefore, many people do not know about their high cholesterol level. A simple blood test can be used to check the cholesterol level of a person.

The metabolic disorder therapeutics market can be segmented based on disease, product, and region. In terms of disease, the metabolic disorder therapeutics market can be divided into lysosomal storage disease, diabetes, obesity, and hypercholesterolemia. The diabetes segment is anticipated to dominate the market because of the extensive use of metabolic disease therapies in anti-diabetic injections and drugs and injections for controlling the blood sugar levels. Based on product, the metabolic disorder therapeutics market can be classified into metachromatic leukodystrophy, hepatic encephalopathy, globoid leukodystrophy, and others.

In terms of region, the metabolic disorder therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the metabolic disorder therapeutics market, due to the presence of key players, rise in prevalence of diabetes and obesity, well-developed health care infrastructure, and increase in health care expenditure. The metabolic disorder therapeutics market in the Asia Pacific is expected to expand at a rapid pace. Increase in patient population, rise in economic development, increase in government initiatives, and rise in awareness are factors propelling the metabolic disorder therapeutics market in the Asia Pacific.

Key players operating in the global metabolic disorder therapeutics market are Sanofi, Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim International GmbH, AstraZeneca, Amgen Inc., Merck KGaA, Actelion Pharmaceuticals Ltd, Biocon, and AbbVie Inc. For gaining a competitive advantage in the metabolic disorder therapeutics market, there is active involvement of key players in different growth strategies such as partnerships, collaborations, agreements, and new product development.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • The Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates are included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.